GlassScriptPhysician profile
Chintan Shah
NPI 1942662770
$4,101.68
in general payments reported to CMS, 2019-2025
18 companies · $72.32 in 2025
The $72.32 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.97 · 2021: $1,833 · 2022: $612 · 2023: $1,423 · 2024: $130 · 2025: $72.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150 · Travel and Lodging: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.16 |
| Travel and Lodging | $475.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,345.11 | 2021-2022 | |
| Boston Scientific Corporation | $933.99 | 2021-2023 | Vercise |
| Merz Pharmaceuticals, LLC | $412.18 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $316.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $250.26 | 2023 | |
| Abbvie INC. | $195.16 | 2021-2024 | Botox, Ubrelvy |
| Abbott Laboratories | $178.85 | 2023-2024 | Infinity |
| Acorda Therapeutics, INC | $117.38 | 2021 | |
| Neurocrine Biosciences, INC. | $81.21 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $73.17 | 2021 | |
| Ge Healthcare | $53.70 | 2023-2024 | |
| Medtronic USA, INC. | $31.97 | 2020 | |
| Janssen Biotech, INC. | $25.36 | 2025 | Rybrevant |
| Argenx US, INC. | $24.03 | 2023 | Vyvgart |
| Tactile Systems Technology INC | $16.87 | 2025 | Nimbl, Flexitouch Plus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.39 | 2025 | Uplizna |
| Philips North America LLC | $16.16 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.70 | 2025 | Alymsys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chintan Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.